<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Celyad Sa — News on 6ix</title>
<link>https://6ix.com/company/celyad-sa</link>
<description>Latest news and press releases for Celyad Sa on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 02 Apr 2026 17:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/celyad-sa" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683619c078dffbe2df13e7d6.webp</url>
<title>Celyad Sa</title>
<link>https://6ix.com/company/celyad-sa</link>
</image>
<item>
<title>Celyad Oncology Reports Full Year 2025 Financial Results and Business Highlights</title>
<link>https://6ix.com/company/celyad-sa/news/celyad-oncology-reports-full-year-2025-financial-results-and-business-highlights</link>
<guid isPermaLink="true">https://6ix.com/company/celyad-sa/news/celyad-oncology-reports-full-year-2025-financial-results-and-business-highlights</guid>
<pubDate>Thu, 02 Apr 2026 17:00:00 GMT</pubDate>
<description>MONT-SAINT-GUIBERT, Belgium, April 02, 2026--Regulatory News: Celyad Oncology (Euronext: CYAD) (the "Company"), today announces its financial results for the fiscal year ended December 31, 2025, and provides a business update.</description>
</item>
<item>
<title>Celyad Oncology Announces the Sale of C-CATHez ® Catheter</title>
<link>https://6ix.com/company/celyad-sa/news/celyad-oncology-announces-sale-c-060000068</link>
<guid isPermaLink="true">https://6ix.com/company/celyad-sa/news/celyad-oncology-announces-sale-c-060000068</guid>
<pubDate>Thu, 12 Feb 2026 06:00:00 GMT</pubDate>
<description>MONT-SAINT-GUIBERT, Belgium, February 12, 2026--Regulatory News: Celyad Oncology (Euronext: CYAD) ("Celyad" or the "Company"), today announced the acquisition by CellProthera of C-Cathez®, the transendocardial catheter originally developed by Celyad Oncology. The acquisition is a decisive step for CellProthera as it prepares to enter Phase 3 clinical trial, with the transendocardial catheter as a cornerstone of its therapeutic approach, enabling targeted delivery of stem cells directly into dama</description>
</item>
<item>
<title>Celyad Oncology: Publication of a Transparency Notification Received From Fortress Investment Group LLC (Article 14 §1 of the Law of 2 May 2007)</title>
<link>https://6ix.com/company/celyad-sa/news/celyad-oncology-publication-transparency-notification-180000080</link>
<guid isPermaLink="true">https://6ix.com/company/celyad-sa/news/celyad-oncology-publication-transparency-notification-180000080</guid>
<pubDate>Tue, 25 Nov 2025 18:00:00 GMT</pubDate>
<description>MONT-SAINT-GUIBERT, Belgium, November 25, 2025--Regulatory News: Celyad Oncology SA (Euronext: CYAD) ("Celyad Oncology" or the "Company") today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Transparency Law"), that it received a notification of transparency dated November 20, 2025, indicating that CFIP CLYD (UK) Limited, an affiliate of Fort</description>
</item>
<item>
<title>Celyad Oncology: Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)</title>
<link>https://6ix.com/company/celyad-sa/news/celyad-oncology-information-total-number-180000029</link>
<guid isPermaLink="true">https://6ix.com/company/celyad-sa/news/celyad-oncology-information-total-number-180000029</guid>
<pubDate>Fri, 14 Nov 2025 18:00:00 GMT</pubDate>
<description>MONT-SAINT-GUIBERT, Belgium, November 14, 2025--Regulatory News: Celyad Oncology (Euronext: CYAD) (the "Company" or "Celyad Oncology"), today announced that 14,903,846 shares of CFIP CLYD (UK) Limited benefit from a double voting right as of November 14, 2025. As a result, the Company’s total number of voting rights is now 72,383,166.</description>
</item>
<item>
<title>Celyad Oncology Announces Research Facility Divestiture</title>
<link>https://6ix.com/company/celyad-sa/news/celyad-oncology-announces-research-facility-163000956</link>
<guid isPermaLink="true">https://6ix.com/company/celyad-sa/news/celyad-oncology-announces-research-facility-163000956</guid>
<pubDate>Mon, 29 Sep 2025 16:30:00 GMT</pubDate>
<description>MONT-SAINT-GUIBERT, Belgium, September 29, 2025--Regulatory News: Celyad Oncology (Euronext: CYAD) (the "Company"), today announces the divestment of the Company’s research facility.</description>
</item>
<item>
<title>Celyad Oncology Reports First Half Year 2025 Financial Results</title>
<link>https://6ix.com/company/celyad-sa/news/celyad-oncology-reports-first-half-163000538</link>
<guid isPermaLink="true">https://6ix.com/company/celyad-sa/news/celyad-oncology-reports-first-half-163000538</guid>
<pubDate>Thu, 25 Sep 2025 16:30:00 GMT</pubDate>
<description>MONT-SAINT-GUIBERT, Belgium, September 25, 2025--Regulatory News: Celyad Oncology (Euronext: CYAD) (the "Company"), today announced its financial results for the first half year 2025 ended June 30, 2025.</description>
</item>
<item>
<title>Celyad Oncology SA: Publication of a Transparency Notification Received From Fortress Investment Group LLC (Article 14 §1 of the Law of 2 May 2007)</title>
<link>https://6ix.com/company/celyad-sa/news/celyad-oncology-sa-publication-transparency-163000886</link>
<guid isPermaLink="true">https://6ix.com/company/celyad-sa/news/celyad-oncology-sa-publication-transparency-163000886</guid>
<pubDate>Thu, 11 Sep 2025 16:30:00 GMT</pubDate>
<description>MONT-SAINT-GUIBERT, Belgium, September 11, 2025--Regulatory News: Celyad Oncology SA (Euronext: CYAD) ("Celyad Oncology" or the "Company") today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Transparency Law"), that it received a notification of transparency dated September 08, 2025, indicating that CFIP CLYD (UK) Limited, an affiliate of Fo</description>
</item>
<item>
<title>Celyad Oncology SA: Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)</title>
<link>https://6ix.com/company/celyad-sa/news/celyad-oncology-sa-information-total-050000413</link>
<guid isPermaLink="true">https://6ix.com/company/celyad-sa/news/celyad-oncology-sa-information-total-050000413</guid>
<pubDate>Thu, 04 Sep 2025 05:00:00 GMT</pubDate>
<description>MONT-SAINT-GUIBERT, Belgium, September 04, 2025--Regulatory News: Celyad Oncology (Euronext: CYAD) ("Celyad" or the "Company"), today announced that 3,849,040 registered shares benefit from a double voting right as of September 4, 2025. As a result, the Company’s total number of voting rights is now 61,335,454.</description>
</item>
<item>
<title>Celyad Oncology Announces Discontinuation of R&D Activities</title>
<link>https://6ix.com/company/celyad-sa/news/celyad-oncology-announces-discontinuation-r-062900791</link>
<guid isPermaLink="true">https://6ix.com/company/celyad-sa/news/celyad-oncology-announces-discontinuation-r-062900791</guid>
<pubDate>Tue, 26 Aug 2025 06:29:00 GMT</pubDate>
<description>MONT-SAINT-GUIBERT, Belgium, August 26, 2025--Regulatory News: Celyad Oncology (Euronext: CYAD) ("Celyad" or the "Company"), today announced that it has decided to discontinue its research and development (R&D) activities and to implement a significant reduction in its R&D workforce due to limited cash resources.</description>
</item>
<item>
<title>Celyad Oncology SA: Publication of a Transparency Notification Received from Fortress Investment Group LLC</title>
<link>https://6ix.com/company/celyad-sa/news/celyad-oncology-sa-publication-transparency-163000639</link>
<guid isPermaLink="true">https://6ix.com/company/celyad-sa/news/celyad-oncology-sa-publication-transparency-163000639</guid>
<pubDate>Wed, 13 Aug 2025 16:30:00 GMT</pubDate>
<description>MONT-SAINT-GUIBERT, Belgium, August 13, 2025--Regulatory News: Celyad Oncology SA (Euronext: CYAD) ("Celyad Oncology" or the "Company") today announces, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Transparency Law"), that it received a notification of transparency dated August 11, 2025, indicating that CFIP CLYD (UK) Limited, an affiliate of Fortress</description>
</item>
<item>
<title>Celyad Oncology Announces €1 Million Private Placement</title>
<link>https://6ix.com/company/celyad-sa/news/celyad-oncology-announces-1-million-200000109</link>
<guid isPermaLink="true">https://6ix.com/company/celyad-sa/news/celyad-oncology-announces-1-million-200000109</guid>
<pubDate>Mon, 28 Jul 2025 20:00:00 GMT</pubDate>
<description>MONT-SAINT-GUIBERT, Belgium, July 28, 2025--Regulatory News: Celyad Oncology (Euronext: CYAD) (the "Company" or "Celyad") today announced that it has entered into a subscription agreement for a private placement financing.</description>
</item>
<item>
<title>Celyad Oncology Announces Strategic Review</title>
<link>https://6ix.com/company/celyad-sa/news/celyad-oncology-announces-strategic-review-170000513</link>
<guid isPermaLink="true">https://6ix.com/company/celyad-sa/news/celyad-oncology-announces-strategic-review-170000513</guid>
<pubDate>Tue, 24 Jun 2025 17:00:00 GMT</pubDate>
<description>MONT-SAINT-GUIBERT, Belgium, June 24, 2025--Regulatory News: Celyad Oncology (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD) (the "Company" or "Celyad") today announced that it is conducting a comprehensive review of strategic alternatives. Given the Company’s current financial position and the general state of biotech market, this review now includes potential asset sales, operational and organizational restructuring, and possible mergers or business combination, in addition to potential financing f</description>
</item>
<item>
<title>Celyad Oncology Reports Full Year 2024 Financial Results and Recent Business Highlights</title>
<link>https://6ix.com/company/celyad-sa/news/celyad-oncology-reports-full-2024-170000411</link>
<guid isPermaLink="true">https://6ix.com/company/celyad-sa/news/celyad-oncology-reports-full-2024-170000411</guid>
<pubDate>Wed, 02 Apr 2025 17:00:00 GMT</pubDate>
<description>MONT-SAINT-GUIBERT, Belgium, April 02, 2025--Regulatory News: Celyad Oncology (Euronext: CYAD) (the "Company"), today announces its financial results for the fiscal year ended December 31, 2024, and provides a business update.</description>
</item>
</channel>
</rss>